Named patient supply for Ark's brain cancer therapy Cerepro in France
This article was originally published in Scrip
Executive Summary
Ark Therapeutics has been permitted by the French medicines control agency (Afssaps) to supply a French neurosurgeon with its gene-based medicine Cerepro (stimagene ceradenovec) to treat a single patient with brain cancer (malignant glioma).